Zura Bio (NASDAQ:ZURA) Trading Up 7.8% – Here’s What Happened

Zura Bio Limited (NASDAQ:ZURA) shares traded up 7.8% during trading on Monday . The stock traded as high as $5.64 and last traded at $5.64. 40,095 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 839,422 shares. The stock had previously closed at $5.23.

Analyst Upgrades and Downgrades

ZURA has been the subject of a number of recent research reports. Wedbush reissued an “outperform” rating and issued a $15.00 target price on shares of Zura Bio in a research note on Wednesday, July 1st. William Blair started coverage on Zura Bio in a research report on Wednesday, July 8th. They set an “outperform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Monday, July 6th. Finally, Wall Street Zen lowered Zura Bio from a “sell” rating to a “strong sell” rating in a research note on Sunday, July 12th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.75.

Zura Bio Price Performance

The stock has a market capitalization of $525.64 million, a PE ratio of -5.08 and a beta of -0.03. The company has a 50 day moving average price of $4.60 and a 200-day moving average price of $5.38.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). As a group, equities analysts anticipate that Zura Bio Limited will post -0.76 earnings per share for the current year.

Institutional Investors Weigh In On Zura Bio

Large investors have recently modified their holdings of the stock. Allworth Financial LP purchased a new position in shares of Zura Bio during the fourth quarter valued at about $30,000. Scientech Research LLC bought a new stake in Zura Bio during the 3rd quarter valued at approximately $45,000. AQR Capital Management LLC purchased a new position in shares of Zura Bio during the 1st quarter worth approximately $72,000. Bank of America Corp DE raised its position in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after acquiring an additional 9,966 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Zura Bio in the 3rd quarter worth approximately $109,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.